Jing Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Huang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Marsha A. Moses
Vascular Biology Program Boston Children's Hospital Boston MA 02115 USA
2 shared publications - Andrew C. Huang
Mabplex International, Yantai, Shandong 264006, China
1 shared publication - Bing Zhu
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
1 shared publication - Daxing Liu
Department of Biomedical Engineering, The City College of New York, 160 Convent Avenue, New York, NY 10031, USA
1 shared publication - Debra T. Auguste
Northeastern University
1 shared publication Gillian Fell
Vascular Biology Program, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
1 shared publication
Latest Publications
- Open Access
- 5 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (18) , eabq7866
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC patients. Here, we report the development of a rationally designed antibody drug conjugate (ADC) for the treatment of late-stage and refractory TNBC. We determined that intercellular adhesion molecule-1 (ICAM1), a cell surface receptor overexpressed in TNBC, efficiently facilitates receptor-mediated antibody internalization. We next constructed a panel of four ICAM1 ADCs using different chemical linkers and warheads and compared their in vitro and in vivo efficacies against multiple human TNBC cell lines and a series of standard, late-stage, and refractory TNBC in vivo models. An ICAM1 antibody conjugated with monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker was identified as the optimal ADC formulation owing to its outstanding efficacy and safety, representing an effective ADC candidate for TNBC therapy.
- 5 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (18) , eabq7866
Open AccessA rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC patients. Here, we report the development of a rationally designed antibody drug conjugate (ADC) for the treatment of late-stage and refractory TNBC. We determined that intercellular adhesion molecule-1 (ICAM1), a cell surface receptor overexpressed in TNBC, efficiently facilitates receptor-mediated antibody internalization. We next constructed a panel of four ICAM1 ADCs using different chemical linkers and warheads and compared their in vitro and in vivo efficacies against multiple human TNBC cell lines and a series of standard, late-stage, and refractory TNBC in vivo models. An ICAM1 antibody conjugated with monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker was identified as the optimal ADC formulation owing to its outstanding efficacy and safety, representing an effective ADC candidate for TNBC therapy.
- Open Access
- 1 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (3) , eaav5010
Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
Dual complementary liposomes inhibit proliferation and metastasis in triple-negative breast cancer.
- 1 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (3) , eaav5010
Open AccessDual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
Dual complementary liposomes inhibit proliferation and metastasis in triple-negative breast cancer.